Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Riley J. Morrow"'
Publikováno v:
STAR Protocols, Vol 4, Iss 1, Pp 102110- (2023)
Summary: Tumor-derived organoids are valuable for testing anti-cancer drugs in vitro, but existing lysis-based protocols for viability measurement are laborious and restricted at a single time point. Here, we provide a lysis-free protocol for longitu
Externí odkaz:
https://doaj.org/article/a32c02ec48f041a9bb47da26cc2dfefe
Autor:
Riley J. Morrow, Amr H. Allam, Josh Konecnik, David Baloyan, Christine Dijkstra, Moritz F. Eissmann, Saumya P. Jacob, Megan O’Brien, Ashleigh R. Poh, Matthias Ernst
Publikováno v:
Cells, Vol 11, Iss 24, p 4104 (2022)
Aberrant expression of the oncoprotein c-Myc (Myc) is frequently observed in solid tumors and is associated with reduced overall survival. In addition to well-recognized cancer cell-intrinsic roles of Myc, studies have also suggested tumor-promoting
Externí odkaz:
https://doaj.org/article/e07f1bdc3de4487b93a8929e1842ee67
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Inflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations. The clinical presentation of inflammatory breast cancer often differs significantly from that of
Externí odkaz:
https://doaj.org/article/9903c23a29024343b697d92f3b1561d3
Autor:
Riley J. Morrow, Amr H. Allam, Belinda Yeo, Siddhartha Deb, Carmel Murone, Elgene Lim, Cameron N. Johnstone, Matthias Ernst
Publikováno v:
Cancers; Volume 14; Issue 9; Pages: 2292
Inflammatory breast cancer (IBC) describes a highly aggressive form of breast cancer of diverse molecular subtypes and clonal heterogeneity across individual tumors. Accordingly, IBC is recognized by its clinical signs of inflammation, associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fed51cd8b30234bbd90e816df7b32a9
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Mediators of Inflammation
Mediators of Inflammation
Inflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations. The clinical presentation of inflammatory breast cancer often differs significantly from that of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a695e762dd79ff6e056eccca729e7d7
https://doi.org/10.1155/2017/4754827
https://doi.org/10.1155/2017/4754827
Autor:
Kelly L. Walton, Andrew M. Allen, Rhiannon Coulson, Natalie J. Hannan, Craig A. Harrison, Ashleigh R Poh, Riley J. Morrow, Beena Kumar, Kyren A. Lazarus, Seng H. Liew, Mariah G. Alorro, Colin Clyne, Ana Cristina Vargas, Matthias Ernst, Tracy L Putoczki, Nicholas S. Yee, Siddhartha Deb, Ashwini L. Chand, Angela A. Connelly, Sandra A O'Toole, Adam C. Parslow, Evie F.W. Yeap, Amee J George
Publikováno v:
ResearcherID
Oncotarget
Oncotarget
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) to manage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995dfb902f4822ad3dc201a534d4de10
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000396879200006&KeyUID=WOS:000396879200006
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000396879200006&KeyUID=WOS:000396879200006
